Medicine · Français

Will Phathom Pharmaceuticals announce topline results from the pHalcon-EoE-201 trial of VOQUEZNA in Eosinophilic Esophagitis by December 31, 2026?

deadline 2026-12-31 confidence medium tier 4 evidence
71%Asturna estimate
⚠ Evidence cap applied: the model proposed 78%, brought back to 71% for lack of sources solid enough to justify the departure from the base rate.

Resolution criterion

Yes if, no later than December 31, 2026, Phathom Pharmaceuticals publicly reports the topline results of the pHalcon-EoE-201 trial of VOQUEZNA (the outcome on the primary endpoint, positive or negative) in a press release or SEC filing. The deadline is the last day of the period the company gave in its filing ("fourth quarter 2026"). An announcement of a delay or of a new timeline, enrollment or interim data that do not report the primary-endpoint outcome, or the absence of any announcement by that date, resolves NO.

Verified starting state

As of October 30, 2026: according to the Phathom Pharmaceuticals filing of October 29, 2026, the company expects topline results in the period "fourth quarter 2026". Source: https://www.sec.gov/Archives/edgar/data/1783183/000119312526436959/d180192dex991.htm

What pushes it up

What pushes it down

What would move this number most

Whether the data readout can be completed and released on schedule without unforeseen delays

How this number is built

Deadline2026-12-31
Base rate65%
Best evidencetier 4 · 1 article(s) used
Independent runs68 · 73 (spread 5 pts)
Confidencemedium
Evidence capapplied: 78% brought back to 71%
Last revised2026-10-30 15:28
Modelopenai/gpt-oss-120b (Groq)

Sources consulted

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)tier 4 · GlobeNewswire · 2026-06-23